Clinical & Experimental Allergy最新文献

{"title":"Low levels of gluten and major milk allergens Bos d 5 and Bos d 11 identified in commercially available honey","authors":"Max D. Bermingham, Karina Klekotko, Maria A. Oliver, J. Blaxland","doi":"10.1111/cea.14159","DOIUrl":"https://doi.org/10.1111/cea.14159","url":null,"abstract":"To the Editor, Despite allergy and allergic reactions to honey being widely regarded as rare, there have been documented systemic allergic reactions following ingestion of honey.1 Current literature suggests that pollens and components derived from bees are the main cause of such reactions.1,2 However, interestingly and perhaps unknown to many allergic patients and allergists, there are also reports of supplementary bee feeding with food allergenloaded mixtures of soybean flour, dried brewer's yeast (containing high levels of residual gluten from brewing processes) and dry skimmed milk with sugar and water.3 Furthermore, there have been reports of mould contamination within beehives.4 Both factors suggest a potential for gluten, food and mould allergen protein presence in honey, which could account for some of the reported reactions following honey consumption. As such, the aim of this study was to determine if commercially available honey contained undeclared gluten and/or food or mould allergens, and at levels which could present a risk to individuals with hypersensitivities. To investigate this, honey samples (n = 40) of UK, EU, NonEU and blended NonEU/EU origin were extracted and analysed for gluten using the Neogen Veratox Gliadin R5 Gluten ELISA, which is regarded as the gold standard for gluten measurements in the food industry. Major allergen content was measured using InBio MARIA and MARIA for Foods quantitative multiplex arrays for cow's milk, egg, peanut, soy, hazelnut, cashew and mould allergens. The MARIA immunoassay is based on xMAP® technology (Luminex Corp.) which uses polystyrene or magnetic microspheres that are internally labelled to create distinct sets of beads. Separate bead sets are covalently coupled with allergenspecific monoclonal antibodies, enabling the simultaneous capture and detection of multiple allergens in a single sample.5 Gluten (gliadin) assays were conducted according to manufacturer instruction. Honey samples were extracted by transferring 250 mg of honey to a 50ml sterile centrifuge tube to which 2.5 ml of renaturing cocktail solution (Neogen 8515, 8515B, 8515S) was added. The resultant suspension was vortex mixed for 30 s and incubated in a water bath at 50°C for 40 min. Samples were then cooled for 10 min at room temperature (RT), and 80% v/v ETOH was added. Samples were mixed as previously described for 20 s and then rotated at 200 rpm for 60 min before 100 μl of the resultant solution was added to 1.25 ml of phosphate buffered saline (PBS). A negative honey control was employed during testing for the presence of Gliadin R 5, this was produced on the day of testing and consisted of; 28 g glucose, 14 g fructose and 8 g of Sterile distilled water. In all tests, the negative control did not produce a result above the assay limit of detection of 2.5 parts per million (ppm) of gliadin, or 5 ppm of gluten. Analysis was repeated on two separate occasions and results are an average of these two measurements. App","PeriodicalId":10148,"journal":{"name":"Clinical & Experimental Allergy","volume":"9 1","pages":"904 - 906"},"PeriodicalIF":0.0,"publicationDate":"2022-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80330673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cochrane corner: Intranasal corticosteroids for non‐allergic rhinitis","authors":"I. Gregory, A. Grewal","doi":"10.1111/cea.14151","DOIUrl":"https://doi.org/10.1111/cea.14151","url":null,"abstract":"Chronic rhinitis, manifesting as sneezing, nasal itching, congestion and rhinorrhoea, is a global health problem affecting up to 40% of the population.1 A quarter to a half of patients with chronic rhinitis have nonallergic rhinitis (NAR), defined as persistent symptoms of rhinitis with no obvious allergic, infectious or anatomical cause.2,3 The treatment options include avoidance of known triggers, medication and surgery. A number of medications are used to treat NAR; however, the role and benefit of individual medications in this multifaceted disease are poorly understood. This review focuses on the use of intranasal corticosteroids for treating NAR and compares it to other medications or no treatment.","PeriodicalId":10148,"journal":{"name":"Clinical & Experimental Allergy","volume":"82 1","pages":"836 - 838"},"PeriodicalIF":0.0,"publicationDate":"2022-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79960559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral food challenge management in Japan: A retrospective analysis of health insurance claims data","authors":"Hisako Ogasawara, Hiroyuki Ohbe, H. Yasunaga","doi":"10.1111/cea.14154","DOIUrl":"https://doi.org/10.1111/cea.14154","url":null,"abstract":"system in Japan, the findings may not apply to other regions or dif-ferent healthcare systems. In conclusion, OFCs are conducted nationwide in general hospitals and clinics, not only in allergy- specialized facilities, as part of daily medical services in Japan. The proportion of anaphylaxis during OFC was relatively low, and there were no life- threatening events in both clinics and hospitals, as exemplified by the low number of adrenaline injections. There were also no life- threatening events during the procedure. However, we should still be very careful when performing OFC in patients with a history of anaphylaxis and wheezing.","PeriodicalId":10148,"journal":{"name":"Clinical & Experimental Allergy","volume":"41 1","pages":"898 - 900"},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89791609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Probiotic peanut oral immunotherapy is associated with long‐term persistence of 8‐week sustained unresponsiveness and long‐lasting quality‐of‐life improvement","authors":"P. Loke, Kuang-Chih Hsiao, A. Lozinsky, S. Ashley, M. Lloyd, Sigrid Pitkin, C. Axelrad, K. Jayawardana, D. Tey, E. Su, M. Robinson, A. Leung, A. Dunn Galvin, M. Tang","doi":"10.1111/cea.14137","DOIUrl":"https://doi.org/10.1111/cea.14137","url":null,"abstract":"Peanut allergy persists for life in the majority of patients. Current management relies on allergen avoidance; however, about 50% of patients have accidental exposures within 1 year. 1 Peanut oral im munotherapy (OIT) is effective at inducing desensitization and can induce sustained unresponsiveness (SU) in a subset of treated pa tients; however, data on long- term effectiveness and health- related quality- of- life (HRQL) impact are lacking. OIT- induced SU may be short- lived, with up to 67% of treatment responders losing their SU within 12 months. 2 Furthermore, a meta- analysis found that peanut OIT was associated with frequent adverse events (AE) and no signif icant improvement in HRQL. 3 We previously reported results from a proof- of- concept random ized trial (PPOIT- 001), which showed that 18- month treatment with combined probiotic and peanut oral immunotherapy (PPOIT) in duced 2- to 6- week SU in 74.2% of children aged 1– 10 years. 4 A long-term follow- up of PPOIT- 001 patients showed that PPOIT- induced SU persisted to 4- year post- treatment in 70% of initial treatment responders. 5 Weaknesses of the parent PPOIT- 001 study included participant selection based upon the clinical history of reaction and positive peanut skin prick test (SPT) or specific- IgE (sIgE) rather than double- blind placebo- controlled food challenge (DBPCFC), and the assessment of SU at 2- to 6- week post- treatment rather than after","PeriodicalId":10148,"journal":{"name":"Clinical & Experimental Allergy","volume":"68 1","pages":"806 - 811"},"PeriodicalIF":0.0,"publicationDate":"2022-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91223106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social and ethical factors in anaphylaxis","authors":"L. Pur Ozyigit, M. Odemyr, E. Bradatan, C. Brall, R. Porz, G. Scadding","doi":"10.1111/cea.14118","DOIUrl":"https://doi.org/10.1111/cea.14118","url":null,"abstract":"","PeriodicalId":10148,"journal":{"name":"Clinical & Experimental Allergy","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82296919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individual‐patient data and aggregate evidence syntheses and the future of allergy‐immunology research","authors":"D. Chu","doi":"10.1111/cea.14144","DOIUrl":"https://doi.org/10.1111/cea.14144","url":null,"abstract":"Systematic summaries of the available evidence are a fundamental component in achieving optimal health outcomes.1 Traditional evidence hierarchies place systematic reviews and metaanalyses at their pinnacle. Metaanalyses (MA) can be subdivided into two analytic approaches: those that primarily combine existing published data using the values reported in individual studies, called ‘aggregate data metaanalysis’, where individual trials are a kind of unit of analysis; and those that seek to combine the raw study data from multiple studies, called ‘individual patient data [IPD] metaanalysis’, where the unit of analysis is individual participants that are clustered within individual studies. IPD metaanalyses have been claimed to be the ‘gold standard’ of evidence synthesis. What are the merits of IPD MA and why are investigators not doing more of them? In this issue, Van Vogt, Cro and colleagues, representing the Skincare interventions for the prevention of atopic dermatitis (SCiPAD) collaboration leadership, report a comparison of aggregate MA vs IPD MA of skin care interventions, primarily moisturizers (emollients), vs standard care for the prevention of atopic dermatitis and IgEmediated food allergy in infants.2 Smartly planned, excellently done, spectacularly interpreted and impactfully informative, they report similar effect estimates using both analytic approaches, and the IPD approach better addressed the betweenstudy heterogeneity, allowed more sophisticated statistical analyses and could","PeriodicalId":10148,"journal":{"name":"Clinical & Experimental Allergy","volume":"4 1","pages":"598 - 599"},"PeriodicalIF":0.0,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89159183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early origins of allergic disease","authors":"R. Boyle, M. Shamji","doi":"10.1111/cea.14142","DOIUrl":"https://doi.org/10.1111/cea.14142","url":null,"abstract":"","PeriodicalId":10148,"journal":{"name":"Clinical & Experimental Allergy","volume":"48 1","pages":"592 - 594"},"PeriodicalIF":0.0,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80152666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palforzia for peanut allergy: Panacea or predicament","authors":"M. Perkin","doi":"10.1111/cea.14145","DOIUrl":"https://doi.org/10.1111/cea.14145","url":null,"abstract":"","PeriodicalId":10148,"journal":{"name":"Clinical & Experimental Allergy","volume":"38 1","pages":"729 - 731"},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81153382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel gain‐of‐function mutation in STAT5B is associated with treatment‐resistant severe atopic dermatitis","authors":"Nurhan Kasap, Kubra Aslan, Leman Tuba Karakurt, H. Bozkurt, H. Canatan, O. Cavkaytar, A. Eken, M. Arga","doi":"10.1111/cea.14148","DOIUrl":"https://doi.org/10.1111/cea.14148","url":null,"abstract":"","PeriodicalId":10148,"journal":{"name":"Clinical & Experimental Allergy","volume":"11 1","pages":"907 - 910"},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81649982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum IL‐22 binding protein as a marker for atopic dermatitis activity and response to dupilumab treatment","authors":"C. Varandas, M. C. Pereira-Santos, Marta Neto, A. Sousa, A. Lopes, Susana L. Silva","doi":"10.1111/cea.14147","DOIUrl":"https://doi.org/10.1111/cea.14147","url":null,"abstract":"We investigated here the interleukin- 22 (IL- 22)/IL- 22 Binding Protein (IL- 22BP) axis in Atopic Dermatitis (AD) and its modulation upon treatment with Dupilumab, and our findings support its relevance in the clinical management of severe AD. IL- 22 has been emerging as an important player in AD, and its serum levels were shown to be increased in moderate- to- severe AD. 1 IL- 22 assumes major cross- talk functions between immune and epithelial cells, promoting epithelia homeostasis and skin barrier integrity. 2,3 However, it should be tightly regulated, as IL- 22 constitutes one of the cytokines which leads to local inflammation, induction of keratinocyte proliferation and inhibition of its terminal differentiation. 3,4 Part of these effects are likely associated with the role of IL- 22 in the regulation of molecules critically involved in skin barrier. 5 Interestingly, recent data showed that targeting IL- 22 may positively impact on severe AD in the subgroup of patients expressing high level of IL- 22 at baseline. 4 This preliminary study evaluating the clinical outcomes of a small cohort of moderate-to- severe AD with the anti- IL- 22 antibody, Fezakinumab, 4 further supports the relevance of the IL- 22 pathway in AD, given the significant improvement of SCORAD at week 20 ( p = .049). Another player in this axis is the IL- 22BP that inhibits the IL- 22 binding to its membrane bound receptor, IL- 22R. 3,6,7 IL- 22BP was shown to bind IL- 22 with a considerable higher affinity, up to 2000fold, than","PeriodicalId":10148,"journal":{"name":"Clinical & Experimental Allergy","volume":"16 1","pages":"820 - 823"},"PeriodicalIF":0.0,"publicationDate":"2022-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89919525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}